Dror Bashan - 11 Apr 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
President and CEO, Director
Signature
/s/ Dror Bashan
Issuer symbol
PLX
Transactions as of
11 Apr 2022
Net transactions value
+$102,000
Form type
4
Filing time
13 Apr 2022, 16:05:46 UTC
Previous filing
28 Feb 2022
Next filing
09 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Purchase $102,000 +68,000 $1.50 68,000 11 Apr 2022 Direct F1
holding PLX Common Stock 1,085,458 11 Apr 2022 By Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person holds the shares in an account with his spouse as joint tenants.
F2 Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.